Target Gene/Pathway(薬物標的遺伝子/パスウェイリスト)
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z other
No. | KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * | KEGG DRUG * | DrugBank | 指定難病告示番号 * |
1 | Acute myeloid leukemia |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
2 | Adipocytokine signaling pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
3 | African trypanosomiasis |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
4 | AGE-RAGE signaling pathway in diabetic complications |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
5 | Allograft rejection |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
6 | Alzheimer disease |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
7 | Amoebiasis |
2件: IL1R1, IL1R2 | D02934 | Anakinra | 17件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
8 | AMPK signaling pathway |
1件: HMGCR | D00434 | Simvastatin | 19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 | ||
1件: PPARG | D00945 | Pioglitazone | 17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 | ||
D08378 | |||||
9 | Amyotrophic lateral sclerosis (ALS) |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
10 | Antifolate resistance |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
11 | Antigen processing and presentation |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
12 | Apelin signaling pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
13 | Apoptosis |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
14 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) |
1件: ITGA4 | D06886 | Natalizumab | 6件: 13, 15, 25, 46, 63, 96 |
15 | Asthma |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
16 | Autophagy - animal |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
17 | Autophagy - other |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
18 | Bile secretion |
1件: HMGCR | D00434 | Simvastatin | 19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
19 | Breast cancer |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
20 | C-type lectin receptor signaling pathway |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
21 | Cell adhesion molecules (CAMs) |
1件: ITGA4 | D06886 | Natalizumab | 6件: 13, 15, 25, 46, 63, 96 |
22 | Cellular senescence |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
23 | Central carbon metabolism in cancer |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
24 | Chagas disease (American trypanosomiasis) |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
25 | Choline metabolism in cancer |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
26 | Colorectal cancer |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
27 | Cytokine-cytokine receptor interaction |
2件: ACVR2A, ACVR2B | D10620 | Bimagrumab | 1件: 15 |
2件: IL1R1, IL1R2 | D02934 | Anakinra | 17件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 | ||
2件: LTA, TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
28 | Dilated cardiomyopathy (DCM) |
1件: ITGA4 | D06886 | Natalizumab | 6件: 13, 15, 25, 46, 63, 96 |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
29 | ECM-receptor interaction |
1件: ITGA4 | D06886 | Natalizumab | 6件: 13, 15, 25, 46, 63, 96 |
30 | EGFR tyrosine kinase inhibitor resistance |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
31 | Endocrine resistance |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
32 | Epstein-Barr virus infection |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
33 | ErbB signaling pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
34 | Fc epsilon RI signaling pathway |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
35 | Fluid shear stress and atherosclerosis |
2件: ACVR2A, ACVR2B | D10620 | Bimagrumab | 1件: 15 |
2件: IL1R1, IL1R2 | D02934 | Anakinra | 17件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 | ||
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
36 | Focal adhesion |
1件: ITGA4 | D06886 | Natalizumab | 6件: 13, 15, 25, 46, 63, 96 |
37 | Gastric cancer |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
38 | Glioma |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
39 | Graft-versus-host disease |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
40 | Growth hormone synthesis, secretion and action |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
41 | Hematopoietic cell lineage |
2件: IL1R1, IL1R2 | D02934 | Anakinra | 17件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
1件: ITGA4 | D06886 | Natalizumab | 6件: 13, 15, 25, 46, 63, 96 | ||
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
42 | Hepatitis B |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
43 | Hepatitis C |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
44 | Hepatocellular carcinoma |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
45 | Herpes simplex virus 1 infection |
2件: LTA, TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 | ||
46 | HIF-1 signaling pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
47 | Human cytomegalovirus infection |
1件: IL1R1 | D02934 | Anakinra | 17件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 | ||
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
48 | Human immunodeficiency virus 1 infection |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
49 | Human papillomavirus infection |
1件: ITGA4 | D06886 | Natalizumab | 6件: 13, 15, 25, 46, 63, 96 |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 | ||
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
50 | Human T-cell leukemia virus 1 infection |
2件: IL1R1, IL1R2 | D02934 | Anakinra | 17件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
2件: LTA, TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
51 | Huntington disease |
1件: PPARG | D00945 | Pioglitazone | 17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
D08378 | |||||
52 | Hypertrophic cardiomyopathy (HCM) |
1件: ITGA4 | D06886 | Natalizumab | 6件: 13, 15, 25, 46, 63, 96 |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
53 | IL-17 signaling pathway |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
54 | Inflammatory bowel disease (IBD) |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
55 | Inflammatory mediator regulation of TRP channels |
1件: IL1R1 | D02934 | Anakinra | 17件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
56 | Influenza A |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
57 | Insulin resistance |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
58 | Insulin secretion |
1件: SNAP25 | D00783 | Botulinum toxin type A | 13件: 2, 5, 6, 7, 13, 15, 17, 36, 51, 70, 113, 149, 226 |
59 | Insulin signaling pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
60 | Intestinal immune network for IgA production |
1件: ITGA4 | D06886 | Natalizumab | 6件: 13, 15, 25, 46, 63, 96 |
61 | JAK-STAT signaling pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
62 | Kaposi sarcoma-associated herpesvirus infection |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
63 | Legionellosis |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
64 | Leishmaniasis |
1件: ITGA4 | D06886 | Natalizumab | 6件: 13, 15, 25, 46, 63, 96 |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
65 | Leukocyte transendothelial migration |
1件: ITGA4 | D06886 | Natalizumab | 6件: 13, 15, 25, 46, 63, 96 |
66 | Longevity regulating pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
1件: PPARG | D00945 | Pioglitazone | 17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 | ||
D08378 | |||||
67 | Longevity regulating pathway - multiple species |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
68 | Malaria |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
69 | MAPK signaling pathway |
1件: IL1R1 | D02934 | Anakinra | 17件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
70 | Metabolic pathways |
1件: HMGCR | D00434 | Simvastatin | 19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
71 | MicroRNAs in cancer |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
72 | mTOR signaling pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
73 | Natural killer cell mediated cytotoxicity |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
74 | Necroptosis |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
75 | NF-kappa B signaling pathway |
1件: IL1R1 | D02934 | Anakinra | 17件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
2件: LTA, TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
76 | NOD-like receptor signaling pathway |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
77 | Non-alcoholic fatty liver disease (NAFLD) |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
78 | Osteoclast differentiation |
1件: IL1R1 | D02934 | Anakinra | 17件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
1件: PPARG | D00945 | Pioglitazone | 17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 | ||
D08378 | |||||
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
79 | Pancreatic cancer |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
80 | Pathogenic Escherichia coli infection |
1件: IL1R1 | D02934 | Anakinra | 17件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
81 | Pathways in cancer |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
1件: PPARG | D00945 | Pioglitazone | 17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 | ||
D08378 | |||||
82 | PD-L1 expression and PD-1 checkpoint pathway in cancer |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
83 | Pertussis |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
84 | Phospholipase D signaling pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
85 | PI3K-Akt signaling pathway |
1件: ITGA4 | D06886 | Natalizumab | 6件: 13, 15, 25, 46, 63, 96 |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 | ||
86 | PPAR signaling pathway |
1件: PPARG | D00945 | Pioglitazone | 17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
D08378 | |||||
87 | Prostate cancer |
1件: IL1R2 | D02934 | Anakinra | 17件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 | ||
88 | Proteoglycans in cancer |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
89 | Regulation of actin cytoskeleton |
1件: ITGA4 | D06886 | Natalizumab | 6件: 13, 15, 25, 46, 63, 96 |
90 | Rheumatoid arthritis |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
91 | RIG-I-like receptor signaling pathway |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
92 | Shigellosis |
1件: IL1R1 | D02934 | Anakinra | 17件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 | ||
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
93 | Signaling pathways regulating pluripotency of stem cells |
2件: ACVR2A, ACVR2B | D10620 | Bimagrumab | 1件: 15 |
94 | Sphingolipid signaling pathway |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
95 | Synaptic vesicle cycle |
1件: SNAP25 | D00783 | Botulinum toxin type A | 13件: 2, 5, 6, 7, 13, 15, 17, 36, 51, 70, 113, 149, 226 |
96 | Systemic lupus erythematosus |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
97 | T cell receptor signaling pathway |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
98 | Terpenoid backbone biosynthesis |
1件: HMGCR | D00434 | Simvastatin | 19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
99 | TGF-beta signaling pathway |
2件: ACVR2A, ACVR2B | D10620 | Bimagrumab | 1件: 15 |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
100 | Th17 cell differentiation |
1件: IL1R1 | D02934 | Anakinra | 17件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 | ||
101 | Thermogenesis |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
1件: PPARG | D00945 | Pioglitazone | 17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 | ||
D08378 | |||||
102 | Thyroid cancer |
1件: PPARG | D00945 | Pioglitazone | 17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
D08378 | |||||
103 | Thyroid hormone signaling pathway |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
104 | TNF signaling pathway |
2件: LTA, TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
105 | Toll-like receptor signaling pathway |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
106 | Toxoplasmosis |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
107 | Transcriptional misregulation in cancer |
1件: IL1R2 | D02934 | Anakinra | 17件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
1件: PPARG | D00945 | Pioglitazone | 17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 | ||
D08378 | |||||
108 | Tuberculosis |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
109 | Type I diabetes mellitus |
2件: LTA, TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
110 | Type II diabetes mellitus |
1件: MTOR | D00753 | Sirolimus | 36件: 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 | ||
111 | Viral protein interaction with cytokine and cytokine receptor |
2件: LTA, TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |
112 | Yersinia infection |
1件: ITGA4 | D06886 | Natalizumab | 6件: 13, 15, 25, 46, 63, 96 |
1件: TNF | D00742 | Etanercept | 15件: 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 |